The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver.
Increased expression of excision repair cross-complementing 1 (ERCC1) in mCRC patients could be related to their response to Oxaliplatin based chemotherapy. We evaluated ERCC1 mRNA expression levels in primary bowel and liver metastases of 51 patients, and correlated with pathologic parameters and clinical outcomes. A significant negative correlation was detected between primary tumor ERCC1 and both the extent of clear surgical margins (P = 0.0011) and the percent of liver metastasis necrosis (P = 0.0167). No relationship was observed between ERCC1 expression and survival. Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.
['Geva|Ravit|R|', 'Shamai|Sivan|S|', 'Brazowsky|Eli|E|', 'Paoulas|Michael|M|', 'Ben-Haim|Mendi|M|', 'Johnstone|Elaine|E|', 'Alex|Beny|B|', 'Shacham-Shmueli|Einat|E|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D000971:Antineoplastic Combined Chemotherapy Protocols D015179:Colorectal Neoplasms D004268:DNA-Binding Proteins D004720:Endonucleases D005260:Female D006801:Humans D008099:Liver D008113:Liver Neoplasms D008297:Male D008875:Middle Aged D020360:Neoadjuvant Therapy D009944:Organoplatinum Compounds D000077150:Oxaliplatin
ERCC1 Oxaliplatin Metastatic colorectal cancer